A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Exclusion Criteria

• •1. Prior histone deacetylases (HDAC), deacetylase (DAC), heat shock protein 90 (HSP90) inhibitors or valproic acid for the treatment of cancer.
• •2. Previous treatment with JAK2 inhibitors.
• •3. Any participant who has previously received radiation therapy to ≥ 30% of the bone marrow.
• •4. Impaired cardiac function or clinically significant cardiac diseases.
• •5. Participant with unresolved diarrhoea ≥ grade 2.
• •6. Participants using medications that have a relative risk of prolonging the QT interval or inducing Torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug.
• •7. Participants who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of surgery.
• •8. Women who are pregnant or breast feeding or women of childbearing potential (WOCBP) not using an effective method of birth control. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). Women of childbearing potential must have a negative serum pregnancy test at screening and at baseline.
• •9. Male participants whose sexual partners are WOCBP not using effective birth control.
• •10. Participants with a prior malignancy with in the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix).
• •11. Participants with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required.